Evaluation of the Efficacy and Safety of Silodosin in the Treatment of the Signs and Symptoms of BPH
Recordati Industria Chimica e Farmaceutica S.p.A.
A new drug for the treatment of benign prostatic hyperplasia is compared with placebo and
tamsulosin (a drug belonging to the same therapeutic class) for to determine if it is safe
and effective (the first phase of the study lasts approximately 18 weeks) and then is used
for another 9 months to determine its long-term safety.
Use of Silodosin to Treat Moderate to Severe Abacterial Chronic Prostatitis/Chronic Pelvic Pain Syndrome.
The primary objective is to compare the efficacy of silodosin 4 and 8 mg once daily with
placebo in the treatment of subjects with moderate to severe abacterial chronic
prostatitis/chronic pelvic pain syndrome during a 12 week treatment period. The secondary
objective is to compare the safety of silodosin 4 and 8 mg once daily with placebo.
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.